L & S Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.9M | Sell |
12,439
-1,738
| -12% | -$1.78M | 1.54% | 9 |
|
|
2026
Q1 | $13M | Sell |
14,177
-574
| -4% | -$582K | 1.64% | 10 |
|
|
2025
Q4 | $15.9M | Buy |
14,751
+3,213
| +28% | +$3.07M | 1.46% | 12 |
|
|
2025
Q3 | $8.8M | Sell |
11,538
-5,563
| -33% | -$4.14M | 0.85% | 36 |
|
|
2025
Q2 | $13.3M | Buy |
17,101
+1,026
| +6% | +$797K | 1.32% | 16 |
|
|
2025
Q1 | $13.3M | Buy |
16,075
+5,326
| +50% | +$4.43M | 1.64% | 11 |
|
|
2024
Q4 | $8.3M | Sell |
10,749
-5,728
| -35% | -$4.74M | 0.91% | 29 |
|
|
2024
Q3 | $14.6M | Sell |
16,477
-2,639
| -14% | -$2.37M | 1.53% | 8 |
|
|
2024
Q2 | $17.3M | Buy |
19,116
+934
| +5% | +$747K | 1.97% | 7 |
|
|
2024
Q1 | $14.1M | Sell |
18,182
-2,631
| -13% | -$1.87M | 1.6% | 7 |
|
|
2023
Q4 | $12.1M | Sell |
20,813
-14,572
| -41% | -$8.51M | 1.48% | 11 |
|
|
2023
Q3 | $19M | Buy |
35,385
+9,270
| +35% | +$4.78M | 2.73% | 2 |
|
|
2023
Q2 | $12.2M | Sell |
26,115
-1,698
| -6% | -$712K | 1.63% | 9 |
|
|
2023
Q1 | $9.55M | Sell |
27,813
-8,371
| -23% | -$2.82M | 1.34% | 14 |
|
|
2022
Q4 | $13.2M | Sell |
36,184
-9,871
| -21% | -$3.5M | 2.45% | 3 |
|
|
2022
Q3 | $14.9M | Buy |
46,055
+7,957
| +21% | +$2.52M | 2.62% | 3 |
|
|
2022
Q2 | $12.4M | Buy |
38,098
+19,812
| +108% | +$5.95M | 2.06% | 4 |
|
|
2022
Q1 | $5.24M | Buy |
18,286
+6,868
| +60% | +$1.77M | 0.62% | 55 |
|
|
2021
Q4 | $3.15M | Buy |
+11,418
| New | +$2.89M | 0.34% | 82 |
|
|
2019
Q2 | – | Sell |
-46,090
| Closed | -$5.98M | – | 346 |
|
|
2019
Q1 | $5.98M | Buy |
46,090
+13,149
| +40% | +$1.6M | 0.8% | 33 |
|
|
2018
Q4 | $3.81M | Buy |
+32,941
| New | +$3.68M | 0.72% | 29 |
|
|
2018
Q1 | – | Sell |
-31,444
| Closed | -$2.66M | – | 318 |
|
|
2017
Q4 | $2.66M | Sell |
31,444
-710
| -2% | -$60.4K | 0.41% | 72 |
|
|
2017
Q3 | $2.75M | Buy |
+32,154
| New | +$2.64M | 0.46% | 66 |
|
|
2017
Q2 | – | Sell |
-72,299
| Closed | -$6.08M | – | 301 |
|
|
2017
Q1 | $6.08M | Buy |
+72,299
| New | +$5.79M | 1.16% | 16 |
|
|
2013
Q4 | – | Sell |
-9,062
| Closed | -$456K | – | 103 |
|
|
2013
Q3 | $456K | Sell |
9,062
-376
| -4% | -$19.7K | 0.18% | 56 |
|
|
2013
Q2 | $464K | Buy |
+9,438
| New | +$514K | 0.23% | 48 |
|
Other funds holding LLY
L & S Advisors's LLY Position: Q2 2026 in Review
L & S Advisors reduced its Eli Lilly (LLY) stake by 12% in Q2 2026, selling an estimated $1.78M and leaving 12,439 shares worth $14.9M. The position accounts for 1.54% of the portfolio, ranked #9.
L & S Advisors first reported a position in LLY in Q2 2013 and has held it in 26 quarters since. The position peaked at $19M in Q3 2023. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- L & S Advisors held 12,439 shares of Eli Lilly worth $14.9M as of Q2 2026.
- L & S Advisors sold 1,738 Eli Lilly shares in Q2 2026, an estimated $1.78M.
- Eli Lilly made up 1.54% of L & S Advisors's portfolio in Q2 2026, its #9 holding.
- L & S Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 26 quarters since.
- L & S Advisors's Eli Lilly position peaked at $19M in Q3 2023.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on L & S Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.